140
Participants
Start Date
March 8, 2024
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
ABBV-969
Intravenous (IV) Infusion
RECRUITING
Chris O'Brien Lifehouse /ID# 261731, Camperdown
RECRUITING
St Vincent's Hospital /ID# 264293, Fitzroy
RECRUITING
Ballarat Base Hospital /ID# 264294, Ballarat
RECRUITING
Hospital Universitario HM Sanchinarro /ID# 271345, Madrid
RECRUITING
Carolina BioOncology Institute /ID# 261602, Huntersville
RECRUITING
AdventHealth Orlando /ID# 261686, Orlando
RECRUITING
START Midwest /ID# 264295, Grand Rapids
RECRUITING
Centre Oscar Lambret /ID# 270602, Lille
RECRUITING
University of Chicago Medical Center /ID# 261605, Chicago
RECRUITING
NEXT Oncology /ID# 261601, San Antonio
RECRUITING
City of Hope /ID# 262059, Duarte
RECRUITING
Hadassah Medical Center-Hebrew University /ID# 261771, Jerusalem
RECRUITING
Institut Gustave Roussy /ID# 270603, Villejuif
RECRUITING
Rambam Health Care Campus /ID# 261770, Haifa
RECRUITING
The Chaim Sheba Medical Center /ID# 261772, Ramat Gan
RECRUITING
Univ California, San Francisco /ID# 261715, San Francisco
RECRUITING
Yale University School of Medicine /ID# 262234, New Haven
RECRUITING
Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687, Providence
RECRUITING
National Cancer Center Hospital East /ID# 261606, Kashiwa-shi
RECRUITING
Kyoto University Hospital /ID# 261861, Kyoto
RECRUITING
National Cancer Center Hospital /ID# 261698, Chuo-ku
RECRUITING
Hospital Universitario Vall de Hebron /ID# 270889, Barcelona
Lead Sponsor
AbbVie
INDUSTRY